ORIGINAL RESEARCH

Properties of RBD specific IgG from COVID-19 patients and Sputnik V vaccinated individuals

About authors

1 Рeoples’ Friendship University of Russia (RUDN University), Moscow, Russia

2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

Correspondence should be addressed: Vladimir A. Gushchin
Gamaleya, 18, str. 9, Moscow, Russia; moc.liamg@adainawow

About paper

Funding: this research was funded by the Ministry of Health of the Russian Federation, Government assignments number № АААА - А20-120113090054-6, Prof. Olga A. Burgasova was also supported by the RUDN University Strategic Academic Leadership Program.

Author contribution: LV Generalova, IV Grigoriev — research planning, experiments preparation and execution, data interpretation and paper draft preparation; IS Kruzhkova, LV Kolobukhina — data interpretation and paper draft preparation; DV Vasina, AP Tkachuk, OA Burgasova, VA Gushchin — research planning, data interpretation and paper draft preparation.

Compliance with ethical standards: the study was approved by the ethics committee of the First Moscow Infectious Diseases Hospital (protocol № 11/А dated November 16, 2020); informed consent was obtained from all study participants.

Received: 2022-01-23 Accepted: 2022-02-08 Published online: 2022-02-16
|
Fig. 1. Immune responses to SARS-CoV-2 in the studied groups. (A) Cohort of hospitalized patients (B) Cohort of vaccinated patients (C) Cohort of healthy vaccinated volunteers. Significant differences are shown as asterisks (Wilcoxon signed-rank test). Me — median time of sampling in groups from the symptoms onset or the initial vaccination as indicated in the axis
Fig. 2. Anti-RBD IgG conversion (A) and avidity dynamics (B) in the studied groups
Fig. 3. Antibody levels in patients with different disease severity
Fig. 4. Comparison of immune responses in different groups. (А) Comparison of unvaccinated convalescent patients and healthy vaccinated volunteers 4–6 months after the infection/vaccination. (B) Comparison of vaccinated and unvaccinated patients in the acute phase of infection (2–3 weeks from symptoms onset). (С) Comparison of anti-RBD IgG conversion in the studied groups. (D) Comparison of sera avidity dynamics in the studied groups. Significant differences are shown as asterisks (Mann–Whitney U test)
Table 1. Study Cohorts. Values are reported as the medians with the range in parentheses
Table 2. Antibody levels and characteristics in cohorts of patients with different disease severity